These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 2654677)

  • 21. [Controversy about using calcium antagonists for treatment of coronary disease and hypertension].
    Głuszek J; Pawlaczyk-Gabriel K
    Przegl Lek; 1997; 54(9):597-601. PubMed ID: 9501678
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blood pressure reduction is not the only determinant of outcome.
    Sever PS; Poulter NR; Elliott WJ; Jonsson MC; Black HR; Sever PS; Poulter NR; Elliott WJ; Jonsson MC; Black HR
    Circulation; 2006 Jun; 113(23):2754-72; discussion 2773-4. PubMed ID: 16769926
    [No Abstract]   [Full Text] [Related]  

  • 23. Should calcium antagonists be first line drugs in hypertension?
    Furberg CD; Psaty BM
    Herz; 1995 Dec; 20(6):365-9. PubMed ID: 8582696
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Calcium antagonists in the treatment of hypertension and heart failure. A comment to recently published results of clinical trials].
    Kjeldsen SE; Westheim AS
    Tidsskr Nor Laegeforen; 1996 Jan; 116(1):77-80. PubMed ID: 8553344
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Calcium antagonists, firstline partners for betablockers in hypertension.
    Bühler FR
    Z Kardiol; 1984; 73 Suppl 2():95-9. PubMed ID: 6152093
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vascular events during antihypertensive treatment.
    Madren EM
    J Fam Pract; 1996 Dec; 43(6):534. PubMed ID: 8969693
    [No Abstract]   [Full Text] [Related]  

  • 27. The nifedipine scare in hypertension: fact or fiction.
    Gambhir DS
    Indian Heart J; 1996; 48(3):227-9. PubMed ID: 8755005
    [No Abstract]   [Full Text] [Related]  

  • 28. The calcium channel blocker controversy - a caution to physicians and pharmacist.
    Eliot L
    J Pharm Pharm Sci; 1998; 1(1):13-4. PubMed ID: 10942968
    [No Abstract]   [Full Text] [Related]  

  • 29. [Drug-induced parkinsonism. Clinical aspects compared with Parkinson disease].
    Errea-Abad JM; Ara-Callizo JR; Aibar-Remón C
    Rev Neurol; 1998 Jul; 27(155):35-9. PubMed ID: 9674021
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Drug-induced Parkinson syndrome: 10 years of drug vigilance].
    Llau ME; Nguyen L; Senard JM; Rascol O; Montastruc JL
    Therapie; 1994; 49(5):459-60. PubMed ID: 7855765
    [No Abstract]   [Full Text] [Related]  

  • 31. [Established blood pressure drug wins out in a comparative study. In hypertension, a diuretic first!].
    Wepner U
    MMW Fortschr Med; 2003 Jan; 145(1-2):10-2. PubMed ID: 12638431
    [No Abstract]   [Full Text] [Related]  

  • 32. Initial therapy of hypertension.
    Med Lett Drugs Ther; 2004 Jul; 46(1186):53-5. PubMed ID: 15237281
    [No Abstract]   [Full Text] [Related]  

  • 33. [Parkinson syndrome, a possible adverse effect of calcium inhibitors].
    Malaterre HR; Lauribe P; Paganelli F; Ramond B; Lévy S
    Arch Mal Coeur Vaiss; 1992 Sep; 85(9):1335-7. PubMed ID: 1290396
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Long-term treatment with calcium antagonists: advantageous effects and risks].
    van Zwieten PA; Tijssen JG; Lie KI; de Leeuw PW
    Ned Tijdschr Geneeskd; 1995 Dec; 139(52):2715-21. PubMed ID: 8569884
    [No Abstract]   [Full Text] [Related]  

  • 35. [Parkinson disease induced by flunarizine].
    de Sá PN; Heinisch LM
    Arq Neuropsiquiatr; 1989 Dec; 47(4):471-3. PubMed ID: 2634389
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Calcium channel blockers in therapy of neurologic diseases].
    Wessely P; Wöber-Bingöl C
    Wien Med Wochenschr; 1993; 143(19-20):514-8. PubMed ID: 8135034
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Parkinson's disease secondary to flunarizine or other drugs].
    Claps A
    Rev Med Chil; 1995 Aug; 123(8):1033-6. PubMed ID: 8657958
    [No Abstract]   [Full Text] [Related]  

  • 38. Impact of ASCOT on hypertension treatment and guidelines in older adults.
    Sheridan R; Baldwin N
    Age Ageing; 2006 May; 35(3):214-7. PubMed ID: 16638764
    [No Abstract]   [Full Text] [Related]  

  • 39. The effects of physical training and flunarizine on walking capacity in intermittent claudication.
    Lepäntalo M; Sundberg S; Gordin A
    Scand J Rehabil Med; 1984; 16(4):159-62. PubMed ID: 6397852
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Calcium antagonists and blood filterability].
    Muggia C; Ranieri MG; Bobba L; Testa F; Martignoni A; Perani G; Finardi G
    Clin Ter; 1987 Nov; 123(4):281-5. PubMed ID: 2972490
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.